NeoPharm CO. LTD (092730) — Cash Flow Quality Index
NeoPharm CO. LTD (092730) has a Cash Flow Quality Index of 0.86x as of September 2025. Operating cash flow of ₩5.88 Billion is below net income of ₩6.86 Billion, suggesting accrual-heavy earnings not yet converted to cash. Explore NeoPharm CO. LTD (092730) cash conversion ratio to assess how effectively this company generates cash.
Cash Flow Quality Index
Operating Cash Flow
Net Income
Data as of
NeoPharm CO. LTD Cash Flow Quality Index (2012–2024)
Historical Cash Flow Quality Index for NeoPharm CO. LTD across 11 annual periods. Values consistently above 1.0x indicate high-quality earnings. Check how aggressively does NeoPharm CO. LTD reinvest cash to assess the company's total reinvestment commitment from operating cash flow.
Annual Cash Flow Quality Index for NeoPharm CO. LTD (2012–2024)
Year-by-year earnings quality comparison for NeoPharm CO. LTD. For live market cap and the full company financial profile, see how much is NeoPharm CO. LTD worth.
| Year | Quality Index | Operating CF (KRW) | Net Income | YoY Change |
|---|---|---|---|---|
| 2024 | 0.81x | ₩18.63 Billion | ₩23.06 Billion | ▼ -19.4% |
| 2023 | 1.00x | ₩23.26 Billion | ₩23.21 Billion | ▼ -6.0% |
| 2022 | 1.07x | ₩18.16 Billion | ₩17.03 Billion | ▼ -12.9% |
| 2021 | 1.22x | ₩21.68 Billion | ₩17.71 Billion | ▲ +30.0% |
| 2020 | 0.94x | ₩17.07 Billion | ₩18.13 Billion | ▼ -5.7% |
| 2019 | 1.00x | ₩19.22 Billion | ₩19.25 Billion | ▼ -5.1% |
| 2018 | 1.05x | ₩16.18 Billion | ₩15.37 Billion | ▲ +14.3% |
| 2017 | 0.92x | ₩10.65 Billion | ₩11.56 Billion | ▼ -22.1% |
| 2016 | 1.18x | ₩9.16 Billion | ₩7.74 Billion | ▼ -33.9% |
| 2015 | 1.79x | ₩6.09 Billion | ₩3.41 Billion | ▲ +105.3% |
| 2012 | 0.87x | ₩564.34 Million | ₩647.76 Million | — |